Clinical Trial Update: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for TQ-B3525 in relapsed/refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN